BACKGROUND: A carboplatin-based chemotherapy regimen was used as primary postoperative therapy in infants with central nervous system (CNS) tumors to limit renal and ototoxicity and to target systemic exposure. METHODS: Fifty-three patients aged <age 3 years with embryonal CNS tumor medulloblastoma (n = 20), ependymoma (EP, n = 21), choroid plexus carcinoma (CPCA, n = 5), and primitive embryonal neoplasms including atypical teratoid rhabdoid tumors (n = 7) were treated with cyclophosphamide, etoposide, and carboplatin. Radiation therapy was used only for residual disease at the end of chemotherapy or disease progression. RESULTS: The response rate after 2 cycles of chemotherapy was 34% (complete response, 13.8%; partial response, 20.7%). Myelosuppression was the dominant toxicity; 2 patients had toxic deaths related to thrombocytopenia with trauma. The 5-year overall survival (OS) was 49% +/- 7%, and the progression-free survival (PFS) was 31% +/- 7%, with a median follow-up of 11.4 years (range, 5.2-15.0 years). For medulloblastoma, the 5-year PFS was 26% +/- 9%; for EP it was 33% +/- 10%; for CPCA it was 80% +/- 18%; and for primitive neuroectodermal and atypical teratoid rhabdoid tumors it was 0%. Localized EP patients with gross total resection who did not undergo radiotherapy had a 5-year PFS of 57% +/- 17% and OS of 71% +/- 16%. Two patients developed late second malignancies; 1 was associated with germline p53 mutation. CONCLUSIONS: The results confirm that carboplatin has similar activity to cisplatin in otherwise similar regimens. Five-year survival data are comparable to those reported in other recent studies, including high-dose chemotherapy studies. Of note is the marked activity in CPCA and gross totally resected EP.
BACKGROUND: A carboplatin-based chemotherapy regimen was used as primary postoperative therapy in infants with central nervous system (CNS) tumors to limit renal and ototoxicity and to target systemic exposure. METHODS: Fifty-three patients aged <age 3 years with embryonal CNS tumor medulloblastoma (n = 20), ependymoma (EP, n = 21), choroid plexus carcinoma (CPCA, n = 5), and primitive embryonal neoplasms including atypical teratoid rhabdoid tumors (n = 7) were treated with cyclophosphamide, etoposide, and carboplatin. Radiation therapy was used only for residual disease at the end of chemotherapy or disease progression. RESULTS: The response rate after 2 cycles of chemotherapy was 34% (complete response, 13.8%; partial response, 20.7%). Myelosuppression was the dominant toxicity; 2 patients had toxic deaths related to thrombocytopenia with trauma. The 5-year overall survival (OS) was 49% +/- 7%, and the progression-free survival (PFS) was 31% +/- 7%, with a median follow-up of 11.4 years (range, 5.2-15.0 years). For medulloblastoma, the 5-year PFS was 26% +/- 9%; for EP it was 33% +/- 10%; for CPCA it was 80% +/- 18%; and for primitive neuroectodermal and atypical teratoid rhabdoid tumors it was 0%. Localized EP patients with gross total resection who did not undergo radiotherapy had a 5-year PFS of 57% +/- 17% and OS of 71% +/- 16%. Two patients developed late second malignancies; 1 was associated with germline p53 mutation. CONCLUSIONS: The results confirm that carboplatin has similar activity to cisplatin in otherwise similar regimens. Five-year survival data are comparable to those reported in other recent studies, including high-dose chemotherapy studies. Of note is the marked activity in CPCA and gross totally resected EP.
Authors: R J Packer; G Perilongo; D Johnson; L N Sutton; G Vezina; R A Zimmerman; J Ryan; G Reaman; L Schut Journal: Cancer Date: 1992-01-15 Impact factor: 6.860
Authors: J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: S L Palmer; O Goloubeva; W E Reddick; J O Glass; A Gajjar; L Kun; T E Merchant; R K Mulhern Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: R K Mulhern; S L Palmer; W E Reddick; J O Glass; L E Kun; J Taylor; J Langston; A Gajjar Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: A Gajjar; R K Mulhern; R L Heideman; R A Sanford; E C Douglass; E H Kovnar; J A Langston; J J Jenkins; L E Kun Journal: J Clin Oncol Date: 1994-06 Impact factor: 44.544
Authors: R L Heideman; E H Kovnar; S J Kellie; E C Douglass; A J Gajjar; A W Walter; J A Langston; J J Jenkins; Y Li; C Greenwald Journal: J Clin Oncol Date: 1995-09 Impact factor: 44.544
Authors: Richard G Grundy; Sophie A Wilne; Claire L Weston; Kath Robinson; Linda S Lashford; James Ironside; Tim Cox; W Kling Chong; Richard H A Campbell; Cliff C Bailey; Rao Gattamaneni; Sue Picton; Nicky Thorpe; Conor Mallucci; Martin W English; Jonathan A G Punt; David A Walker; David W Ellison; David Machin Journal: Lancet Oncol Date: 2007-08 Impact factor: 41.316
Authors: Giles W Robinson; Vasilisa A Rudneva; Ivo Buchhalter; Catherine A Billups; Sebastian M Waszak; Kyle S Smith; Daniel C Bowers; Anne Bendel; Paul G Fisher; Sonia Partap; John R Crawford; Tim Hassall; Daniel J Indelicato; Frederick Boop; Paul Klimo; Noah D Sabin; Zoltan Patay; Thomas E Merchant; Clinton F Stewart; Brent A Orr; Jan O Korbel; David T W Jones; Tanvi Sharma; Peter Lichter; Marcel Kool; Andrey Korshunov; Stefan M Pfister; Richard J Gilbertson; Robert P Sanders; Arzu Onar-Thomas; David W Ellison; Amar Gajjar; Paul A Northcott Journal: Lancet Oncol Date: 2018-05-16 Impact factor: 41.316
Authors: Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening Journal: Cochrane Database Syst Rev Date: 2019-03-11
Authors: Dong-Anh Khuong-Quang; Lauren M Brown; Marie Wong; Chelsea Mayoh; Alexandra Sexton-Oates; Amit Kumar; Mark Pinese; Sumanth Nagabushan; Loretta Lau; Louise E Ludlow; Andrew J Gifford; Michael Rodriguez; Jayesh Desai; Stephen B Fox; Michelle Haber; David S Ziegler; Jordan R Hansford; Glenn M Marshall; Mark J Cowley; Paul G Ekert Journal: Cold Spring Harb Mol Case Stud Date: 2020-12-17